• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Calcitonin-gene related peptide antagonist therapy associated with microvascular complications in patients with Raynaud’s Phenomenon

byPiero CalcagnoandMichael Pratte
June 2, 2021
in Chronic Disease, Hematology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Microvascular complications were uncommon but nevertheless observed when individuals with Raynaud’s phenomenon (RP) or scleroderma were treated with Calcitonin-gene related peptide (CGRP) antagonist therapy.

2. Microvascular complications in patients with RP included facial telangiectasia and necrosis of distal phalanges after CGRP antagonists use.

Evidence Rating: 2 (Good)

Study Rundown: Raynaud’s phenomenon (RP), a medical condition predominant in females causing pallor and pain in the toes and fingers due to cold temperatures and stress, is often associated with migraines. Recently, calcitonin-gene related peptide antagonists (CGRP) have been approved as a class of therapeutics for migraine therapy; however, its safety in individuals with RP remains unknown. The objective of this study was to characterize the complications of  CGRP usage in individuals with RP. The study involved a review of patients’ medical data from the Mayo Clinic Database (Minnesota, Arizona, Florida) which included 169 RP and scleroderma patients who have used or are currently using CGRP antagonists, and have a history of migraines. Out of the 169 patients, 9 patients suffered from microvascular complications after receiving CGRP antagonist therapy. Complications included exacerbation of RP, digital ulcerations, facial telangiectasia, hematoma, and distal phalange necrosis. Patients who had complications and those who did not were analyzed and had no significant differences amongst each other regarding demographic characteristics (sex, gender, ethnicity) and clinical characteristics. The study reveals that out of the 9 individuals who experienced complications, 4 of them were newly diagnosed with RP, implying that the duration of RP might not influence complications, although this small sample size makes drawing conclusions difficult. The researchers also found that complications in patients with RP were uncommon and not limited to one particular CGRP antagonist. Limitations to the study’s findings include the study did not report from the geographical location of their patients It was also found that the 9 patients with complications had increased β-adrenergic blockers usage. Controlling for these variables is important, as cold temperatures and use of β-Adrenergic blockers exacerbate RP symptoms. Despite these findings, the sample size who experienced complications was small; further investigations into CGRP antagonist use in individuals with RP is needed.

Click to read study in JAMA Network Open here

Relevant Reading: Raynaud’s Phenomenon Associated With Calcitonin Gene‐Related Peptide Monoclonal Antibody Antagonists

In-depth [retrospective cohort]: This study was done to investigate the possibility of complications in people with RP, who used CGRP antagonist migraine therapy from May 2018- September 2020. The search was done using data from the Mayo Clinic in Minnesota, Arizona, and Florida. The initial search for patients with RP or scleroderma had a population of 29,422. The number of patients who used CGRP antagonist from this population was 274, and from the 274 a total of 169 were selected for review based on history of migraine primary or secondary to RP. Of the 169 patients, 9 of them had complications and made up the experimental population, while the remaining 160 were the control population. The control group had a 96.3% female population with a median age of 46 (SD=14) and the experimental group had a 100% female population with a median age of 40 (SD=12). The 9 patients can be classified by 4 different groups of CGRP antagonist usage. 4 patients were on 70mg erenumab, 1 patient on 140mg erenumab, 3 patients on 120mg galcanezumab. The patients can also be categorized by the microvascular complications. 4 patients had microvascular complications which resolved without the need to stop CGRP usage, 1 patient required cessation of 70mg erenumab, 2 patients had continued complications, hematoma of finger and newly diagnosed RP requiring Nadolol chronic treatment respectively, and 2 patients had complications not associated with RP. These symptoms included persistent telangiectasia and distal phalange necrosis which required amputation.

RELATED REPORTS

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

Atogepant effective in reducing migraine and headache days

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: migraineRaynaud's Phenomenon
Previous Post

Aspirin treatment without indication in patients on direct oral anticoagulants may increase the risk of bleeding events

Next Post

Epidural labor analgesia not associated with increased risk of autism spectrum disorder in offspring

RelatedReports

Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

November 14, 2022
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Emergency

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

October 11, 2021
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Chronic Disease

Atogepant effective in reducing migraine and headache days

October 4, 2021
Galcanezumab reduces the frequency of episodic cluster headaches
Neurology

More omega-3 and less omega-6 fatty acid consumption associated with reduced migraine frequency and severity

September 3, 2021
Next Post
Social networks play key roles in parental vaccination decisions

Epidural labor analgesia not associated with increased risk of autism spectrum disorder in offspring

Earlier puberty associated with increased risk of depression in girls

Comparative efficacy of psychotherapies for reducing self-harm and suicidality in young individuals shows inconsistent and low-quality evidence

#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options